InMed Q2 net loss $2.6M, cash burn continues; BayMedica profitable amid revenue drop

InMed Pharmaceuticals Inc.

2025-Q2 EPS reported -$6.43 revenue$2,376,345

Q2 net loss $2.6M vs $1.5M YoY; BayMedica revenue $1.1M (-10% YoY).
Cash $3.5M at Dec 31, 2024; raised $2.9M in Jan 2025; expects funding through Q2 2025.
INM-901 Alzheimer's preclinical data reduced neuroinflammatory markers; INM-089 IVT formulation for dry AMD.
Director Janet Grove resigned after withheld votes at Dec 2024 AGM; board to find replacement.
BayMedica net income $0.23M (+189%) despite revenue drop due to cost cuts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.